What is KPV?
KPV is a tripeptide (lysine–proline–valine), the C-terminal fragment of the hormone α-MSH. It is studied for anti-inflammatory effects in the gut and skin. It is not an FDA-approved drug.
What the evidence shows
Most KPV evidence comes from laboratory and animal models of inflammation. Human clinical-trial data establishing benefit and safety for any indication is limited. It was among the substances the FDA treated as raising safety concerns under its 2023 Category 2 action.
Is it legal?
KPV is not FDA-approved. In April 2026 it was removed from FDA Category 2 but not moved to the approved Category 1 list, so legal compounding is not authorized; the PCAC reviews it on July 23, 2026.
Will KPV become legal in 2026?+
Is “research-grade” KPV the same as a medicine?+
Primary sources: FDA 503A interim list · FDA Advisory Committee Calendar; Federal Register docket FDA-2025-N-6895.
Medical & editorial disclaimer. This article is independent reference information, not medical advice and not a recommendation to use any substance. KPV is not FDA-approved. Nothing here should be used to obtain, prepare, or self-administer any drug. Talk to a licensed clinician about your health. Peptide Docket is not affiliated with the FDA and does not sell peptides.